These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37923152)

  • 1. Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style.
    Zuo Q; Park NH; Lee JK; Santaliz-Casiano A; Madak-Erdogan Z
    Steroids; 2024 Mar; 203():109330. PubMed ID: 37923152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
    Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A
    Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
    Sharma N; Chakole S; Wandile B
    Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
    Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
    Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogens and female liver health.
    Chen KL; Madak-Erdogan Z
    Steroids; 2018 May; 133():38-43. PubMed ID: 29100781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives.
    Venetsanaki V; Polyzos SA
    Curr Vasc Pharmacol; 2019; 17(6):546-555. PubMed ID: 29992886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.
    Liu L; Fu Q; Li T; Shao K; Zhu X; Cong Y; Zhao X
    PLoS One; 2022; 17(2):e0262855. PubMed ID: 35108315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk.
    Morán-Costoya A; Proenza AM; Gianotti M; Lladó I; Valle A
    Antioxid Redox Signal; 2021 Sep; 35(9):753-774. PubMed ID: 33736456
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
    Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Arab JP; Arrese M; Trauner M
    Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.